Physician profile
Alan Serure
NPI 1003962184
$7,721.13
in general payments reported to CMS, 2019-2025
9 companies · $76.75 in 2025
The $76.75 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,646 · 2020: $195 · 2021: $21.28 · 2022: $210 · 2023: $383 · 2024: $189 · 2025: $76.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,791.89 | 2019-2022 | |
| Stryker Corporation | $172.86 | 2023 | Spy-Phi System |
| Galderma Laboratories, L.P. | $144.47 | 2024 | |
| Tela Bio, INC. | $144.14 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $138.64 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $136.80 | 2019 | |
| Abbvie INC. | $95.94 | 2024-2025 | |
| Dilon Technologies, INC. | $71.20 | 2023 | Hemoblast Bellows |
| Solta Medical, A Division of Bausch Health US, LLC | $25.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Serure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.